Clinical Trials Logo

Urogenital Abnormalities clinical trials

View clinical trials related to Urogenital Abnormalities.

Filter by:

NCT ID: NCT04661072 Recruiting - Clinical trials for Congenital Uterine Anomaly

Congenital Uterine Anomalies: Identifying Cancer Associations and Genetic and Environmental Factors to Improve Clinical Care

Start date: July 14, 2021
Phase:
Study type: Observational

The purpose of this research study is to learn more about the health outcomes associated with congenital uterine anomalies (CUAs), and the possible environmental and genetic causes of the condition. The researchers plan to investigate whether any cancer associations (with breast, renal, ovarian, vaginal and uterine cancers) exist in females with CUAs. The investigator will also investigate any environmental and genetic factors that may be responsible for causing CUAs.

NCT ID: NCT03898440 Completed - Prenatal Disorder Clinical Trials

Fetal Ano-genital Distance in 2D Ultrasound.

DAG
Start date: April 15, 2019
Phase:
Study type: Observational

The purpose of this study is to determine a threshold value of fetal anogenital distance in 2D ultrasound to differentiate male fetuses from female fetuses, starting 18 weeks of gestation and until the due date. The study also evaluates the feasibility of the measure and its interobserver variability.

NCT ID: NCT03718234 Completed - Clinical trials for Congenital Disorders

Subcutaneous Hydrocortisone Children With Congenital Adrenal Hyperplasia

Start date: January 1, 2019
Phase: Phase 1
Study type: Interventional

This is an open-label, non-randomized crossover design feasibility trial comparing oral hydrocortisone treatment with interval bolus delivery (pulsatile) of subcutaneous hydrocortisone via infusion pump in children with congenital adrenal hyperplasia. Eight children, ages 4-18 yrs, will have 24-hr pharmacokinetic and pharmacodynamic profiles of cortisol, 17-hydroxyprogesterone and androstenedione concentrations while on oral hydrocortisone therapy (admission 1), during an initial trial of the subcutaneous hydrocortisone pump (admission 2), and after 6 weeks of subcutaneous hydrocortisone pump treatment (admission 3). An integrated pharmacokinetic and pharmacodynamic model will be used to determine cortisol, 17-hydroxyprogesterone and androstenedione parameters to compare the duration of time subjects have these concentrations outside acceptable ranges. Funding Source - FDA OOPD

NCT ID: NCT03482141 Completed - Skeletal Anomalies Clinical Trials

Clinical Utility of Prenatal Whole Exome Sequencing

PWES
Start date: August 1, 2017
Phase: N/A
Study type: Interventional

The investigator aims to examine the clinical utility of WES, including assessment of a variety of health-related and reproductive outcomes in undiagnosed prenatal cases.

NCT ID: NCT03295175 Withdrawn - Clinical trials for Congenital Urogenital Anomaly

Distribution of Smooth Muscle In Dartos In The Non Conspicuous Penis

DISMUD
Start date: September 21, 2017
Phase:
Study type: Observational [Patient Registry]

Non-conspicuous penis (congenital megaprepuce, occult penis) is a symptomatic malformation that includes phimosis and excessively baggy, urine-filled prepuce with alteration of the appearance of the penis. A redundant and enlarged foreskin is the main feature of this entity.This congenital anomaly is difficult to diagnose and may have association with other pathologies such as buried penis. Currently, part of the megaprepuce skin is used to correct the defect. A recent study shows that patients with this pathology and hypospadias present mostly defects in the muscle dartos. The investigators do not know the physiological bases of the megaprepuce, neither the clinical and aesthetics implications of this abnormal tissue for the patient, and how this affects the postoperative evolution. With the present study the investigators intended to answer these questions and to open paths for future research in this area.

NCT ID: NCT03185169 Terminated - Clinical trials for Breast Cancer Female

GSM (Genitourinary Syndrome Of Menopause) Management In Breast Cancer Survivors

GSM
Start date: November 18, 2016
Phase: Early Phase 1
Study type: Interventional

The impact of treatment for GSM on the quality of life will be examined for postmenopausal women (defined as last menstrual period > 1 year ago or 6 months ago with FSH >40) who have been diagnosed with breast cancer.

NCT ID: NCT03061084 Recruiting - Spina Bifida Clinical Trials

Prospective Cohort of Transitional Urology Patients

Start date: August 27, 2015
Phase:
Study type: Observational

A transitional Urology database was created in parallel with National Spina Bifida registry to follow patients with complex congenital urogenital anomalies and be able to prospectively evaluate them. The investigators obtained the standardized questionnaires to collect long-term data regarding patients' genitourinary status including urine and fecal continence, sexuality, fertility, and pelvic health.

NCT ID: NCT01831141 Recruiting - Clinical trials for Congenital Solitary Kidney

Long Term Outcome of Congenital Solitary Kidney

CSKP
Start date: June 2010
Phase: N/A
Study type: Observational

Congenital solitary kidney (CSK) is a disorder caused by an abnormal development of one of the two kidneys. The reported incidence ranges between 1:450-3200. It is debated whether CSK is a benign condition or not. A variable risk of developing proteinuria (11-27%), hypertension (0-60%) and chronic kidney damage (3.5-30%) is described. This knowledge derives mainly from retrospective studies performed in tertiary medical centers which is difficult to compare for the following reasons: the number of individuals evaluated, the length of follow-up and the outcome studied. The aim of this longitudinal study is to assess, in a cohort of children with congenital solitary kidney, during a 10 year follow-up period: 1) the rates of developing proteinuria, hypertension and chronic kidney disease and the corresponding potential prognostic factors. 2) the role of new biomarkers of glomerular (Cystatin C) or tubular damage (NGAL, NAG, B2-microglobulin) in predicting the appearance of chronic kidney damage.

NCT ID: NCT01493791 Withdrawn - Clinical trials for Urogenital Abnormalities

CDB-2914 for Abnormal Uterine Bleeding in Premenopausal Women

Start date: November 8, 2011
Phase: Early Phase 1
Study type: Interventional

Background: - CDB-2914 is a hormone that blocks progesterone, which is necessary for maintaining pregnancy. In women with fibroid tumors, CDB-2914 shrank the tumors. In many cases, menstrual periods stopped during treatment. Because CDB-2914 decreased or stopped menstrual bleeding in women with fibroids, it may be able to treat abnormal periods in women without fibroids. Objectives: - To see whether CDB-2914 can treat abnormal uterine bleeding in premenopausal women. Eligibility: - Premenopausal women who have abnormal uterine bleeding that is not caused by fibroids. Design: - Participants will be screened with a physical exam and medical history. They will also have blood and urine tests. An ultrasound with fluid of the uterus will test for fibroids. Uterine cells will be collected for biopsy. - For the next three menstrual cycles, participants will take either CDB-2914 or a placebo. Treatment will be studied with blood tests and symptom diaries. - At the end of the treatment, participants have three options. They can have surgery at the Clinical Center or have another 3 months of CDB-2914. The third option is to stop treatment at the Clinical Center. - Surgery will be either uterine ablation or hysterectomy. Only women older than age 33 may have a hysterectomy. Blood and urine samples will be collected after surgery. - Both surgery and further treatment participants will have followup exams. - All participants will have a final followup exam 1 year after stopping treatment....

NCT ID: NCT01487616 Recruiting - Clinical trials for Congenital Uterine Anomalies

Prevalence of Congenital Uterine Malformations

PUMA
Start date: September 2012
Phase: N/A
Study type: Observational

Aims: We plan to investigate how common uterine malformations are in high-risk women (with history of miscarriage or preterm delivery), by analysing different characteristics in these groups. This study will also investigate other ultrasound characteristics detected on these women. This study will point towards the possible mechanism of how uterine malformations may affect pregnancy outcomes.